Michael Dietrich

Michael Dietrich is the Vice-President of Market Access and Policy at Innovative Medicines Canada (IMC), an organization representing patented drug manufacturers. He has been vocal about the implications of U.S. drug pricing policies, suggesting that the recent push by the Trump administration for drugmakers to disclose confidential contract details should serve as a wake-up call for Canada, prompting a reassessment of how pharmaceuticals are handled in trade discussions.